380 related articles for article (PubMed ID: 25471132)
1. Extrachromosomal driver mutations in glioblastoma and low-grade glioma.
Nikolaev S; Santoni F; Garieri M; Makrythanasis P; Falconnet E; Guipponi M; Vannier A; Radovanovic I; Bena F; Forestier F; Schaller K; Dutoit V; Clement-Schatlo V; Dietrich PY; Antonarakis SE
Nat Commun; 2014 Dec; 5():5690. PubMed ID: 25471132
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
[TBL] [Abstract][Full Text] [Related]
3. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.
Vitucci M; Irvin DM; McNeill RS; Schmid RS; Simon JM; Dhruv HD; Siegel MB; Werneke AM; Bash RE; Kim S; Berens ME; Miller CR
Neuro Oncol; 2017 Sep; 19(9):1237-1247. PubMed ID: 28398584
[TBL] [Abstract][Full Text] [Related]
5. Glioblastomas harboring gene fusions detected by next-generation sequencing.
Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
[TBL] [Abstract][Full Text] [Related]
6. Structure and evolution of double minutes in diagnosis and relapse brain tumors.
Xu K; Ding L; Chang TC; Shao Y; Chiang J; Mulder H; Wang S; Shaw TI; Wen J; Hover L; McLeod C; Wang YD; Easton J; Rusch M; Dalton J; Downing JR; Ellison DW; Zhang J; Baker SJ; Wu G
Acta Neuropathol; 2019 Jan; 137(1):123-137. PubMed ID: 30267146
[TBL] [Abstract][Full Text] [Related]
7. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
8. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
9. EGFR tyrosine kinase domain mutations in human gliomas.
Marie Y; Carpentier AF; Omuro AM; Sanson M; Thillet J; Hoang-Xuan K; Delattre JY
Neurology; 2005 Apr; 64(8):1444-5. PubMed ID: 15851741
[TBL] [Abstract][Full Text] [Related]
10. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
[TBL] [Abstract][Full Text] [Related]
11. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
12. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
14. Patterns of epidermal growth factor receptor amplification in malignant gliomas.
Sauter G; Maeda T; Waldman FM; Davis RL; Feuerstein BG
Am J Pathol; 1996 Apr; 148(4):1047-53. PubMed ID: 8644846
[TBL] [Abstract][Full Text] [Related]
15. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
[TBL] [Abstract][Full Text] [Related]
16. Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas.
Karunasena E; McIver LJ; Rood BR; Wu X; Zhu H; Bavarva JH; Garner HR
Oncotarget; 2014 Aug; 5(15):6003-14. PubMed ID: 25153720
[TBL] [Abstract][Full Text] [Related]
17. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations associated with glioma progression.
Kleihues P; Lübbe J; Watanabe K; von Ammon K; Ohgaki H
Verh Dtsch Ges Pathol; 1994; 78():43-7. PubMed ID: 7534015
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathologic diagnosis of epidermal growth factor receptor.
Maire CL; Ligon KL
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii1-6. PubMed ID: 25342599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
